P2Y₁₂ Inhibitors in Chronic Coronary Syndromes Undergoing Elective PCI: Any Niche for Potent Agents?

JACC Cardiovasc Interv. 2024 Feb 12;17(3):371-373. doi: 10.1016/j.jcin.2023.12.032.

Author

José Luis Ferreiro¹

Affiliation

¹ Department of Cardiology, Joan XXIII University Hospital-IISPV, CIBER-CV, Tarragona, Spain. Electronic address: [email protected].

PMID: 38355266
DOI: 10.1016/j.jcin.2023.12.032

No abstract available

Keywords: P2Y(12) inhibitors; antiplatelet therapy; chronic coronary syndrome; elective percutaneous coronary intervention.

Publication types

Editorial

MeSH terms

Acute Coronary Syndrome* / diagnostic imaging
Acute Coronary Syndrome* / therapy
Humans
Percutaneous Coronary Intervention* / adverse effects
Platelet Aggregation Inhibitors / adverse effects
Purinergic P2Y Receptor Antagonists / adverse effects
Ticlopidine
Treatment Outcome

Substances

Platelet Aggregation Inhibitors
Ticlopidine
Purinergic P2Y Receptor Antagonists